Drug Trial Radar · NCT06383013
BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
May 1, 2024
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Blue Blood Biotech Corp.Industry
- Sponsor type
- Industry
- First posted
- Apr 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.
Conditions
- Diabetic Foot Ulcer
Interventions
BB-101Biological
Subjects will be randomized to receive BB-101 or placebo, and expected 32 subjects for each arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy EvaluationTime frame: 4 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan · Recruiting
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare
Taipei, Taiwan · Recruiting
Wanfang Hospital
Taipei, Taiwan · Not yet recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.